This monthly Grand Rounds program is aimed at topics which align with Mayo Clinic's position as a global leader in research and education, the professional interests of participants in London and the importance of sharing knowledge on timely topics/issues.
|Future Webinars for Mayo Clinic Healthcare London Grand Rounds Series|
Session 3: Mayo Clinic Healthcare London Grand Rounds - Gastrointestinal
In this one-hour no-cost Grand Rounds session from Mayo Clinic Healthcare in London, our experts will discuss colorectal cancer development and new techniques to enhance detection and resection of serrated polyps, as well as endoscopic management of bariatric and metabolic disorders.
Session 4: MCH London Grand Rounds - Advancing The Paradigm: Personalized Genomic Approach to Breast Cancer Risk Assessment- Impact on Screening and Prevention
In this one-hour no-cost Grand Rounds session from Mayo Clinic Healthcare in London, our experts will discuss breast cancer risk assessment, which entails understanding clinical and genomic risk factors. Available risk calculation models provide population level risk with limitations in implementation in clinical practice. We need to advance the paradigm and transition to precision prevention and personalized risk stratification. With accurate risk assessment clinicians can optimize clinical benefits including surveillance imaging and risk reducing medication options. New research on the use of single nucleotide polymorphisms and polygenic risk score could be useful for stratifying and predicting individualized breast cancer risk and enhance shard decision making opportunities in management of women at increased risk for breast cancer.
|Next Expected Session(s) sign up to be notified of these and future Mayo Clinic Healthcare London Grand Rounds Series|
Session 5: September, 2022
|Mayo Clinic Healthcare London Grand Rounds Series|
Session 2: Mayo Clinic Healthcare London Grand Rounds - Management of Left Main Coronary Artery Disease
Session 1: Mayo Clinic Healthcare London Grand Rounds - The Latest on Covid-19 Advances March 1, 2022